erlotinib hydrochloride has been researched along with Capsule Opacification in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Braun, C; Eibl-Lindner, K; Kassumeh, S; Kueres, A; Mayer, W; Priglinger, C; Priglinger, S; Siedlecki, J; Wertheimer, C; Wolf, A | 1 |
| Docheva, D; Eibl-Lindner, KH; Kampik, A; Kernt, M; Liegl, R; Mayer, W; Wertheimer, C | 1 |
2 other study(ies) available for erlotinib hydrochloride and Capsule Opacification
| Article | Year |
|---|---|
The intraocular lens as a drug delivery device for an epidermal growth factor-Receptor inhibitor for prophylaxis of posterior capsule opacification.
Topics: Adult; Aged; Capsule Opacification; Cell Line; Cell Movement; Cell Proliferation; Drug Delivery Systems; Endothelium, Corneal; ErbB Receptors; Erlotinib Hydrochloride; Humans; Lenses, Intraocular; Middle Aged; Organ Culture Techniques; Posterior Capsule of the Lens; Protein Kinase Inhibitors; Tissue Donors; Young Adult | 2018 |
EGF receptor inhibitor erlotinib as a potential pharmacological prophylaxis for posterior capsule opacification.
Topics: Adult; Aged; Capsule Opacification; Cell Line; Cell Movement; Cell Proliferation; Dose-Response Relationship, Drug; Epithelial Cells; ErbB Receptors; Erlotinib Hydrochloride; Humans; Middle Aged; Neuroglia; Posterior Capsule of the Lens; Protein Kinase Inhibitors; Quinazolines; Retinal Pigment Epithelium | 2013 |